| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 20
| Issue : 2 | Page : 104-110 |
|
|
Medical management of patients with benign prostatic hyperplasia: A study in Indian population
Amit Kumar Shah1, Anand Srivastava1, SC Karan2
1 Department of Urology and Surgery, INHS Asvini, Mumbai, Maharashtra, India
2 Department of Urology and Renal Transplant, Columbus Hospital, Ghaziabad, Uttar Pradesh, India
Correspondence Address:
Lt Col Amit Kumar Shah
Department of Surgery, INHS Asvini, Colaba, Mumbai - 400 005, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmms.jmms_22_18
|
|
|
Introduction: At present, the geriatric population has formed a large clientele for medical services, with an increased incidence of lifestyle diseases. Approach to lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is an upcoming challenge, especially with management showing a paradigm shift toward medical management. This study was basically designed to study the outcome of medical management of BPH on Indian population following the recommendations based on recent guidelines on medical management of BPH. Materials and Methods: With a calculated sample size of 131 based on the prevalence of BPH, a total of 170 patients were enrolled, and their complete profile with clinical examination, imaging and International Prostatic Symptom Score details were taken as per proforma and were followed up while on medical management and assessed on a cross-sectional basis at regular intervals. Results: The mean age in the study group was 64.61 years. We recorded that all patients had some formal education. These patients were prescribed α-1ablockers as monotherapy or combination therapy as per the protocol of the study. They showed improvement while on medical management with significant improvement. Adverse reactions of medical management were not significant enough to warrant discontinuation of therapy. Forty-one patients out of 170 underwent surgery for no response or worsening quality of life. This group was further analyzed which revealed that comorbid condition, prostate size, and body mass index had no association with the outcome. Conclusion: There is sufficient evidence to support the paradigm shift in the management of BPH. The present guideline is to initiate medical management with monotherapy for patients with BPH and prostate size <30 g and combination therapy for larger prostate sized >30 g. Surgery is advised for patients who do not respond to medical therapy and for the subgroup of patients with absolute indication for surgery in BPH. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
